Corpus ID: 14558648

Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.

@article{Miyagi2001InductionOC,
  title={Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.},
  author={Yoshiaki Miyagi and Nobue Imai and Teruo Sasatomi and Akira Yamada and Takashi Mine and Kazuko Katagiri and Masami Nakagawa and Akira Muto and Satoko Okouchi and Hiroharu Isomoto and Kazuo Shirouzu and Hideaki Yamana and Kyogo Itoh},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2001},
  volume={7 12},
  pages={
          3950-62
        }
}
  • Y. Miyagi, N. Imai, +10 authors K. Itoh
  • Published 2001
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
The tumor-rejection antigen SART3 possesses two antigenic epitopes (SART3(109-118) and SART3(315-323)) capable of inducing HLA-A24-restricted and tumor-specific CTLs. To determine its safety and ability to generate antitumor immune responses, 12 patients with advanced colorectal cancer were administered s.c. vaccinations of these peptides. No severe adverse events were associated with the vaccinations. Significant levels of increased cellular immune responses to both HLA-A24+ colon cancer cells… Expand
Immunological evaluation of CTL precursor‐oriented vaccines for advanced lung cancer patients
TLDR
Peptide‐specific IgG became detectable in post‐vaccination sera in 4 of 10 patients tested, and these 4 patients had a long progression‐free survival, which encourages further development of CTL precursor‐oriented peptide vaccination for lung cancer patients. Expand
A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients
TLDR
Post-vaccination peripheral blood mononuclear cells from five patients demonstrated an increased peptide-specific immune response to the peptides, which encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients. Expand
Peptide Vaccination for Patients With Melanoma and Other Types of Cancer Based on Pre-existing Peptide-Specific Cytotoxic T-Lymphocyte Precursors in the Periphery
TLDR
Results indicate that peptide vaccination of patients showing evidence of pre-existing peptide-specific CTL precursors can be applied in further clinical trials aimed at the treatment of melanoma and other types of cancer. Expand
Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients
TLDR
Whether cytotoxic T lymphocytes-precursors reacting to 28 kinds of peptides of vaccine candidates were detectable in pre-vaccination peripheral blood mononuclear cells of 80 cancer patients was investigated and may provide a scientific basis for the development of a new approach to cancer immunotherapy, e.g.) cytot toxic T lymphocyteprecursor-oriented peptide vaccine. Expand
Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre‐existing cellular response to peptide
TLDR
Prolonged survival was observed in patients showing cellular and humoral immune responses to the vaccinated peptides in the post‐vaccination samples, including all 4 patients with the scirrhous type, which encourage further development of peptide‐based immunotherapy for GC patients. Expand
The role of CD8+ T cells in immune responses to colorectal cancer
TLDR
The present review describes the properties and functions of CTL as effectors of the immune response against tumours, and summarises the known TAA recognised by CTL and the current status of C TL-related immunotherapeutic interventions in colorectal cancer patients. Expand
Immunologic Evaluation of Personalized Peptide Vaccination for Patients with Advanced Malignant Glioma
TLDR
Personalized peptide vaccinations were recommended for the further clinical study to malignant glioma patients, and significant levels of peptide-specific IgG were detected in the postvaccination tumor cavity or spinal fluid of all of the tested patients who showed favorable clinical responses. Expand
Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinoma.
TLDR
This study attempted to determine which antigens and their peptides are useful in specific immunotherapy for bladder carcinoma (BC) patients, especially those with human leukocyte antigen (HLA)-A24+ alleles, and reported on antigen-derived peptides which efficiently induced peptide-specific and BC cell-reactive CTLs from HLA-A 24+ BC patients. Expand
Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses
TLDR
Peptide-specific IgG in postvaccination sera could be a suitable laboratory maker for the prediction of prolonged survival in advanced cancer patients vaccinated with peptides based on pre-existing CTL precursors. Expand
Capability of SART 3109-118 peptide to induce cytotoxic T lymphocytes from prostate cancer patients with HLA class I-A 11 ,-A 31 andA 33 alleles
We previously reported the SART3 gene to be a tumor-rejection antigen gene encoding a peptide at positions 109-118 (SART3 109-118) with the ability to induce HLA-A24-restricted cytotoxic TExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
TLDR
Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination. Expand
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
TLDR
A synthetic peptide, designed to increase binding to HLA-A2 molecules, was used as a cancer vaccine to treat patients with metastatic melanoma and, on the basis of immunologic assays, 91% of patients could be successfully immunized with this peptide. Expand
Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
  • F. Wang, E. Bade, +5 authors J. Weber
  • Medicine
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1999
TLDR
A significant proportion of patients with resected melanoma mount an antigen-specific immune response against a peptide vaccine and support further development of peptide vaccines for melanoma. Expand
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
TLDR
It is suggested that the combined treatment with immune-modulating doses of chemotherapy and the GM-CSF-secreting neu vaccine can overcome immune tolerance and induce an antigen-specific antitumor immune response in patients with cancer. Expand
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases
TLDR
It is demonstrated that the lck gene encodes antigenic epitopes recognized by the HLA class I‐restricted and tumor‐specific CTL of metastatic cancer patients and could be useful in developing a specific immunotherapy for cancer patients with distant metastases. Expand
A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes
TLDR
A gene encoding antigenic peptides of human squamous cell carcinomas (SCCs) recognized by human histocompatibility leukocyte antigens (HLA)- A2601–restricted CTLs is identified and may be useful for the specific immunotherapy of HLA-A2601+ epithelial cancer patients. Expand
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
TLDR
One of the 9-mer peptides, AAGIGILTV, was most effective in sensitizing the T2 cells for TIL lysis and appears to be a very common immunogenic epitope for HLA-A2-restricted melanoma-specific TIL and may be useful for the development of immunotherapeutic strategies. Expand
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
TLDR
Evidence is provided that oligopeptides such as PSA-OP may be useful candidates for peptide-based cancer vaccines and it is demonstrated that it is possible to induce CTL responses in HLA-A2.1/Kb transgenic mice by immunization with Psa-OP with adjuvant. Expand
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1
TLDR
The results suggest that injection of the MAGE‐3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. Expand
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.
TLDR
A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line, and it appears to be presented by HLA-A1; anti-MZ 2-E CTLs of the original patient recognized two melanomas cell lines of other HLA -A1 patients that expressed the gene. Expand
...
1
2
3
4
...